Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
Lyndra Therapeutics, Inc. is developing LYN-005, a long-acting oral (LAO) capsule (LYNX™
dosage form) of risperidone. This pivotal study (LYN-005-C-301) will evaluate the PK as well
as safety and tolerability of multiple administrations of the LYN-005 formulation at two dose
levels.